(NASDAQ: RVPH) Reviva Pharmaceuticals Holdings's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.73%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.6%.
Reviva Pharmaceuticals Holdings's earnings in 2025 is -$29,918,802.On average, 3 Wall Street analysts forecast RVPH's earnings for 2025 to be -$32,717,964, with the lowest RVPH earnings forecast at -$38,326,758, and the highest RVPH earnings forecast at -$26,641,771.
In 2026, RVPH is forecast to generate -$21,967,776 in earnings, with the lowest earnings forecast at -$31,783,165 and the highest earnings forecast at -$12,152,387.